NCT06492564 - Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 1

Low dose, approximately 10\^4 TCID50/mL

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 2

Medium dose, approximately 10\^5 TCID50/mL

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 3

High dose, approximately 10\^6 TCID50/mL

Trial Locations (1)

hVIVO Services Ltd, 40 Bank Street, Canary Wharf, London